Search results
Showing 76 to 89 of 89 results for statins
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.
This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
CG181/2 | What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a...
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
NICE has today (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.
NICE approves ground-breaking cholesterol-lowering drug inclisiran
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.
Statins should be offered to everyone who has chronic kidney disease, says NICE
Healthcare professionals should offer statins to millions of people with chronic kidney disease (CKD). This will help to manage their increased risk of cardiovascular disease (CVD), says NICE.
Thousands with high cholesterol set to benefit from new treatment on the NHS
Thousands of people with high cholesterol will soon have access to a new treatment option on the NHS as a result of final NICE guidance published today (28 April 2021).